Analysis of Primary CD30+ Cutaneous Lymphoproliferative Disease and Survival From the Surveillance, Epidemiology, and End Results Database

Abstract

Localized PCLPDs are rare diseases with an excellent overall survival and occur more frequently in whites and in men. Head and neck skin primary site may be associated with poorer survival. CONCLUSIONS regarding subsets demonstrating association with survival should be taken with caution, given the small number of deaths analyzed.

Incidence and survival patterns of cutaneous T-cell lymphomas in the United States

“…It is possible that this new classification scheme, already adopted by EORTC before 2005, did not reflect a true change in clinical practice. It also has been hypothesized previously that LyP given its regressing course is less likely to be reported to a local cancer registry, [31] so the majority of cases in the SEER may be primary cutaneous anaplastic large-cell lymphoma (pcALCL). Our 2-year survival rates were closer to the survival rate of pcALCL,[4] supporting the hypothesis of a greater proportion pcALCL cases.…”

“…Some epidemiologic studies have included both, [5] while others excluded 9718. [31] Additional limitations of this analysis include missing or incomplete data on race (6.6%) and in case of MF/SS patients, missing information on stage (25%). The SEER registries minimize biases introduced by missing data by rigorous evaluation for data quality and completeness, resulting in case ascertainment ≥98% of cases across all SEER registries.…”

Comprehensive analysis of cutaneous T‐cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy

“…Consistent with the initial 2005 World Health Organization‐European Organization for Research and Treatment of Cancer and the updated 2016 WHO classifications of primary cutaneous lymphoma, CTCL cases were defined based on ICD‐O‐3 codes . Primary site of skin was coded 44.0 through 44.9, and CTCL diagnoses were coded, as described above, for MF (ICD‐O‐3 code 9700), SS (code 9701), mature T‐cell lymphoma (MTCL) NOS (code 9702), angioimmunoblastic T‐cell lymphoma (code 9705), subcutaneous panniculitis‐like T‐cell lymphoma (code 9708), CTCL NOS (code 9709), CD30‐positive T‐cell lymphoproliferative disorders of the skin (codes 9714 and 9718), ENKL (code 9719); and ATLL (code 9827) . The CTLC subtypes analyzed in this study are identical to those analyzed in the landmark CTCL incidence studies conducted in the United States …”

Cutaneous Anaplastic Large Cell Lymphoma and Peripheral T-Cell Lymphoma NOS Show Distinct Chromosomal Alterations and Differential Expression of Chemokine Receptors and Apoptosis Regulators

“…C-ALCL has an indolent clinical behavior and rarely shows extracutaneous dissemination. This cutaneous T-cell lymphoma (CTCL) is commonly treated with radiotherapy and has an excellent prognosis with an estimated 5-year survival exceeding 90% (Bekkenk et al, 2000;Liu et al, 2003;Yu et al, 2008). In contrast, primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTL-NOS) presents with more generalized skin tumors and displays aggressive clinical behavior (Willemze et al, 2005).…”